Merck KGaA (OTCMKTS:MKKGY) Cut to “Hold” at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft lowered shares of Merck KGaA (OTCMKTS:MKKGY) from a buy rating to a hold rating in a report published on Tuesday, MarketBeat reports.

Merck KGaA Trading Down 2.0%

Shares of Merck KGaA stock opened at $28.78 on Tuesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.97 and a current ratio of 1.49. The company has a market capitalization of $18.60 billion, a P/E ratio of 11.47, a PEG ratio of 5.95 and a beta of 0.96. Merck KGaA has a 1 year low of $24.32 and a 1 year high of $31.00. The company’s fifty day moving average is $28.93 and its two-hundred day moving average is $27.07.

Merck KGaA (OTCMKTS:MKKGY) last announced its earnings results on Thursday, November 13th. The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.27. Merck KGaA had a net margin of 13.92% and a return on equity of 10.07%. The business had revenue of $6.17 billion during the quarter, compared to analysts’ expectations of $6.08 billion. Analysts forecast that Merck KGaA will post 1.87 earnings per share for the current year.

Merck KGaA Company Profile

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.